SCHEMBL18906100

SCHEMBL18906100

CC(C)(C)NS(=O)(=O)c1ccc([C@@H]2[C@@H](CO)C2(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
MAPT P10636 2/20 0.43
LMNA P02545 4/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
MAPK1 P28482 1/20 0.40
NAMPT P43490 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
CA9 Q16790 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
TSHR P16473 1/20 0.38
HPGD P15428 2/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18906101 1.00 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPTLMNACYP3A4
SCHEMBL18912409 0.80 LMNA (0.46) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL18912282 0.80 LMNA (0.46) ALDH1A1SMN1; SMN2MAPTLMNAMAPK1
SCHEMBL16819953 0.78 CA2 (0.44) CA12CA1CA2CA9
SCHEMBL16819914 0.78 CA2 (0.44) CA12CA1CA2CA9
SCHEMBL18938370 0.78 CA2 (0.44) CA12CA1CA2CA9
SCHEMBL18906102 0.73 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2MAPTLMNACYP3A4
SCHEMBL9821148 0.72 LMNA (0.38) ALDH1A1SMN1; SMN2MAPTLMNATSHR
SCHEMBL18888966 0.71 MAOA (0.38)
SCHEMBL15559251 0.69 GAA (0.37) TSHRMEN1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994518-B2 Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof MERCK SHARP & DOHME CORP. (US) 2018-06-12 US disclosed
US-20170152221-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2017-06-01 US disclosed
US-20170152221-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF MERCK SHARP & DOHME CORP. (US) 2017-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170152221-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF CHRNA7, CHRNA10, CHRNA5 ALDH1A1 708/4885SMN1; SMN2 1781/4885MAPT 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.